Eyal C. Attar

11.1k total citations · 2 hit papers
117 papers, 4.5k citations indexed

About

Eyal C. Attar is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Eyal C. Attar has authored 117 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Hematology, 37 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Eyal C. Attar's work include Acute Myeloid Leukemia Research (56 papers), Hematopoietic Stem Cell Transplantation (27 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Eyal C. Attar is often cited by papers focused on Acute Myeloid Leukemia Research (56 papers), Hematopoietic Stem Cell Transplantation (27 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Eyal C. Attar collaborates with scholars based in United States, France and United Kingdom. Eyal C. Attar's co-authors include Lenny Dang, Katharine Yen, Karen K. Ballen, David T. Scadden, Yih-Woei C. Fridell, Edison T. Liu, Benjamin L. Ebert, Azra Raza, Naomi Galili and Cindy Chang and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Eyal C. Attar

114 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

2008 629 citations Eyal C. Attar et al. profile →
IDH mutations in cancer and progress toward development of targeted therapeutics

2016 363 citations Lenny Dang, Katharine Yen et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eyal C. Attar United States	32	2.3k	2.1k	994	949	843	117	4.5k
Ali G. Turhan France	37	2.0k 0.9×	1.5k 0.7×	1.4k 1.4×	1.0k 1.1×	473 0.6×	184	4.0k
Yogen Saunthararajah United States	38	2.8k 1.2×	2.7k 1.3×	1.4k 1.4×	584 0.6×	804 1.0×	164	5.1k
Steffen Koschmieder Germany	37	2.4k 1.0×	2.8k 1.3×	1.7k 1.7×	730 0.8×	708 0.8×	222	5.2k
Nikolas von Bubnoff Germany	31	2.0k 0.8×	1.1k 0.5×	1.3k 1.3×	1.1k 1.2×	708 0.8×	138	4.1k
Sergej Konoplev United States	35	2.2k 0.9×	1.4k 0.7×	1.2k 1.3×	1.4k 1.5×	1.1k 1.3×	154	4.6k
Robert Månsson Sweden	34	2.2k 1.0×	2.6k 1.2×	759 0.8×	623 0.7×	2.5k 3.0×	73	5.6k
Beatrice U. Mueller Switzerland	26	2.1k 0.9×	2.2k 1.1×	558 0.6×	612 0.6×	483 0.6×	64	3.7k
Raphaël Itzykson France	31	2.9k 1.2×	3.5k 1.7×	1.5k 1.5×	2.0k 2.1×	534 0.6×	139	6.7k
Marı́a José Calasanz Spain	43	2.2k 0.9×	3.0k 1.4×	1.1k 1.1×	866 0.9×	455 0.5×	153	5.1k
Thomas Prébet France	32	2.9k 1.2×	2.0k 1.0×	1.0k 1.0×	735 0.8×	596 0.7×	171	4.2k

Countries citing papers authored by Eyal C. Attar

Since Specialization

Citations

This map shows the geographic impact of Eyal C. Attar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eyal C. Attar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eyal C. Attar more than expected).

Fields of papers citing papers by Eyal C. Attar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eyal C. Attar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eyal C. Attar. The network helps show where Eyal C. Attar may publish in the future.

Co-authorship network of co-authors of Eyal C. Attar

This figure shows the co-authorship network connecting the top 25 collaborators of Eyal C. Attar. A scholar is included among the top collaborators of Eyal C. Attar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eyal C. Attar. Eyal C. Attar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garcia‐Manero, Guillermo, Aaron D. Goldberg, Eric S. Winer, et al.. (2023). Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. The Lancet Haematology. 10(4). e272–e283. 53 indexed citations

Mishra, Asmita, Roni Tamari, Amy E. DeZern, et al.. (2022). Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Following Allogeneic Hematopoietic Cell Transplantation (HCT). Transplantation and Cellular Therapy. 28(3). S34–S35. 1 indexed citations

Shapiro, Geoffrey I., Amit Mahipal, Jason S. Starr, et al.. (2022). Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 7(5). 100573–100573. 34 indexed citations

Stein, Eytan M., Amir T. Fathi, Courtney D. DiNardo, et al.. (2020). Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. The Lancet Haematology. 7(4). e309–e319. 79 indexed citations

Choe, Sung, Hongfang Wang, Courtney D. DiNardo, et al.. (2019). Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia. Blood. 134(Supplement_1). 545–545. 4 indexed citations

Stone, Richard M., Sung Choe, Vickie Zhang, et al.. (2017). Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML. Blood. 130. 2684–2684. 1 indexed citations

Dang, Lenny, Katharine Yen, & Eyal C. Attar. (2016). IDH mutations in cancer and progress toward development of targeted therapeutics. Annals of Oncology. 27(4). 599–608. 363 indexed citations breakdown →

Blonquist, Traci M., Areej El‐Jawahri, Amir T. Fathi, et al.. (2015). The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience. Blood. 126(23). 3318–3318. 2 indexed citations

Fathi, Amir T., Daniel J. DeAngelo, Kristen E. Stevenson, et al.. (2014). Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium. Blood. 124(21). 3714–3714. 2 indexed citations

10.

Coutré, Steven, Megan Othus, Bayard L. Powell, et al.. (2014). Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British Journal of Haematology. 165(4). 497–503. 28 indexed citations

11.

Perry, Ashley & Eyal C. Attar. (2014). New Insights in AML Biology From Genomic Analysis. Seminars in Hematology. 51(4). 282–297. 10 indexed citations

12.

Brunner, Andrew M., Traci M. Blonquist, Hossein Sadrzadeh, et al.. (2014). Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis. Leukemia Research. 38(7). 773–780. 25 indexed citations

13.

Ziakas, Panayiotis D., Theodora Anagnostou, Erin Coughlin, et al.. (2013). Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience. Biology of Blood and Marrow Transplantation. 19(8). 1190–1196. 47 indexed citations

14.

Amrein, Philip C., Eyal C. Attar, Tak Takvorian, et al.. (2011). Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 17(9). 2977–2986. 100 indexed citations

15.

Sykes, Stephen M., Lars Bullinger, Rukh Yusuf, et al.. (2011). Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias. Experimental Hematology. 39(8). 1 indexed citations

16.

Sykes, Stephen M., Steven Lane, Lars Bullinger, et al.. (2011). AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias. Cell. 146(5). 697–708. 217 indexed citations

17.

Singh, Harshabad, Lillian Werner, Daniel J. DeAngelo, et al.. (2011). Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD. American Journal of Hematology. 86(7). 625–627. 7 indexed citations

18.

Attar, Eyal C. & Robert P. Hasserjian. (2010). Case 27-2010. New England Journal of Medicine. 363(11). 1060–1068.

19.

Dey, Bimalangshu R., Stephen S. Chung, Thomas R. Spitzer, et al.. (2010). Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure. Transplantation. 90(8). 905–911. 88 indexed citations

20.

Attar, Eyal C., et al.. (2005). Silencing p21Waf1/Cip1/Sdi1 expression increases gene transduction efficiency in primitive human hematopoietic cells. Gene Therapy. 12(19). 1444–1452. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact